Inventor · disambiguated record
Shyra Gardai
Also filed as: GARDAI SHYRA · GARDAI SHYRA J · GARDAI SHYRA JANE
8 granted patents·30 pending applications·4 citations·filing 2011–2025
78Inventor score
Top patents by PatentIndex Score
38 records- 0182US11202827B2Dosage and administration of non-fucosylated anti-CD40 antibodiesSEAGEN INC·Filed 2017·Granted Dec 21, 2021·2 cites·170 claims
- 0281US2024075134A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2023·Application pending·0 cites
- 0380US2024075135A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2023·Application pending·0 cites
- 0479US2023201344A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2022·Application pending·0 cites
- 0578US2023201343A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2022·Application pending·0 cites
- 0678US2022265822A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2022·Application pending·0 cites
- 0777US2022249662A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2022·Application pending·0 cites
- 0876US11401339B2Anti-TIGIT antibodiesSEAGEN INC·Filed 2019·Granted Aug 2, 2022·1 cites·122 claims
- 0973US11891644B2T cells with reduced surface fucosylation and methods of making and using the sameSEAGEN INC·Filed 2018·Granted Feb 6, 2024·1 cites·8 claims
- 1070US2024117400A1T cells with reduced surface fucosylation and methods of making and using the sameSEAGEN INC·Filed 2023·Application pending·0 cites
- 1169US2023279133A1Modulating the immune response using antibody-drug conjugatesSEAGEN INC·Filed 2022·Application pending·0 cites
- 1269US2025066507A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2024·Application pending·0 cites
- 1363US12071480B2CD47 antibodies and uses thereof for treating cancerSEAGEN INC·Filed 2021·Granted Aug 27, 2024·0 cites·33 claims
- 1463US2023050440A1Anti-TIGIT AntibodiesSEAGEN INC·Filed 2022·Application pending·0 cites
- 1563US2024166757A1Methods of treating cancer with nonfucosylated anti-cd70 antibodiesSEAGEN INC·Filed 2023·Application pending·0 cites
- 1662US2025255981A1Immunomodulatory antibody-drug conjugatesSEAGEN INC·Filed 2023·Application pending·0 cites
- 1762US2024123079A1Immunomodulatory antibody-drug conjugatesSEAGEN INC·Filed 2023·Application pending·0 cites
- 1861US2024025998A1Methods of Treating Cancer with Anti-TIGIT AntibodiesSEAGEN INC·Filed 2023·Application pending·0 cites
- 1960US11213584B2Dosage and administration of non-fucosylated anti-CD40 antibodiesSEAGEN INC·Filed 2015·Granted Jan 4, 2022·0 cites·46 claims
- 2060US2025009877A1Treatment for cancerSEAGEN INC·Filed 2022·Application pending·0 cites
- 2160US2023110128A1Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumorSEAGEN INC·Filed 2022·Application pending·0 cites
- 2259US2023117205A1B7-h4 antibody-drug conjugates for the treatment of cancerSEAGEN INC·Filed 2022·Application pending·0 cites
- 2358US2024165229A1Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonistSEAGEN INC·Filed 2022·Application pending·0 cites
- 2457US11820827B2Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodiesSEAGEN INC·Filed 2020·Granted Nov 21, 2023·0 cites·22 claims
- 2557US2025090875A9Immunostimulatory compounds and conjugatesSEAGEN INC·Filed 2023·Application pending·0 cites
- 2654US11180552B2CD47 antibodies and uses thereof for treating cancerSEAGEN INC·Filed 2018·Granted Nov 23, 2021·0 cites·33 claims
- 2754US2020239585A1Modulating the immune response using antibody-drug conjugatesSEATTLE GENETICS INC·Filed 2018·Application pending·0 cites
- 2854US2023203175A1Anti-CD40 Antibody Combination Treatment for CancerSEAGEN INC·Filed 2021·Application pending·0 cites
- 2954US2021107980A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Application pending·0 cites
- 3052US2023270877A1Combination TherapySEAGEN INC·Filed 2023·Application pending·0 cites
- 3148US2015353631A1C-terminal and central epitope a-beta antibodiesJANSSEN ALZHEIMER IMMUNOTHERAP·Filed 2013·Application pending·0 cites
- 3248US2019290775A1Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid TumorSEATTLE GENETICS INC·Filed 2019·Application pending·0 cites
- 3346US2025295801A1Cd25 antibodies, antibody drug conjugates, and uses thereofSEAGEN INC·Filed 2025·Application pending·0 cites
- 3444US2023027495A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2020·Application pending·0 cites
- 3542US2014186294A1Phagocytic activity as a marker of synucleinopathic diseaseGARDAI SHYRA·Filed 2011·Application pending·0 cites
- 3639US2018353524A1Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitorSEATTLE GENETICS INC·Filed 2016·Application pending·0 cites
- 3739US2025388682A1Degradation of egfr using a bispecific binding agentEPIBIOLOGICS INC·Filed 2025·Application pending·0 cites
- 3838US12324841B2Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Granted Jun 10, 2025·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Shyra Gardai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →